Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
about
A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor ActivityAnti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivoObatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
P2860
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Orally active microtubule-targ ...... in combination with erlotinib
@ast
Orally active microtubule-targ ...... in combination with erlotinib
@en
type
label
Orally active microtubule-targ ...... in combination with erlotinib
@ast
Orally active microtubule-targ ...... in combination with erlotinib
@en
prefLabel
Orally active microtubule-targ ...... in combination with erlotinib
@ast
Orally active microtubule-targ ...... in combination with erlotinib
@en
P2093
P2860
P356
P1476
Orally active microtubule-targ ...... in combination with erlotinib
@en
P2093
P2860
P2888
P356
10.1038/CDDIS.2014.128
P577
2014-04-10T00:00:00Z
P6179
1050950555